

Trying 3106016892...Open

Welcome to STN International! Enter x:x

LOGINID:sssptal653hxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 Sep 29 The Philippines Inventory of Chemicals and Chemical  
Substances (PICCS) has been added to CHEMLIST  
NEWS 3 Oct 27 New Extraction Code PAX now available in Derwent  
Files  
NEWS 4 Oct 27 SET ABBREVIATIONS and SET PLURALS extended in  
Derwent World Patents Index files  
NEWS 5 Oct 27 Patent Assignee Code Dictionary now available  
in Derwent Patent Files  
NEWS 6 Oct 27 Plasdoc Key Serials Dictionary and Echoing added to  
Derwent Subscriber Files WPIDS and WPIX  
NEWS 7 Nov 29 Derwent announces further increase in updates for DWPI  
  
NEWS EXPRESS FREE UPGRADE 5.0DP1 FOR STN EXPRESS 5.0 WITH DISCOVER!  
(WINDOWS) NOW AVAILABLE  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 16:37:43 ON 30 NOV 2000

=> file medline,

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.15	0.15

FILE 'MEDLINE' ENTERED AT 16:37:58 ON 30 NOV 2000

FILE LAST UPDATED: 27 OCT 2000 (20001027/UP). FILE COVERS 1960 TO DATE.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the

MeSH 2000 vocabulary. Enter HELP THESAURUS for details.

The OLDMEDLINE file segment now contains data from 1966 through 1965.  
Enter HELP CONTENT for details.

Left, right, and simultaneous left and right truncation are available in the Basic Index. See HELP SFIELDS for details.

THIS FILE CONTAINS CAS REGISTRY NUMBERS FOR EASY AND ACCURATE  
SUBSTANCE IDENTIFICATION.

=> s angiogenesis and (induction)

8235 ANGIOGENESIS  
191343 INDUCTION  
L1 669 ANGIOGENESIS AND (INDUCTION)

=> s muetin

L2 0 MUETIN

=> s l1 and composition

107302 COMPOSITION  
L3 2 L1 AND COMPOSITION

=> d l3 ti abs ibib tot

L3 ANSWER 1 OF 2 MEDLINE

TI Mitogen-induced expression of the fibroblast growth factor-binding  
protein

AB is transcriptionally repressed through a non-canonical E-box element.  
The fibroblast growth factor-binding protein (FGF-BP) stimulates  
FGF-2-mediated **angiogenesis** and is thought to play an important  
role in the progression of squamous cell, colon, and breast carcinomas.  
12-O-Tetradecanoylphorbol-13-acetate (TPA) **induction** of the  
FGF-BP gene occurs through transcriptional mechanisms involving Sp1,  
AP-1,

and CCAATT/enhancer-binding protein sites in the proximal FGF-BP gene  
promoter. The level of TPA **induction**, however, is limited due to  
the presence of a repressor element that shows similarity to a  
non-canonical E-box (AACGTG). Mutation or deletion of the repressor  
element led to enhanced **induction** by TPA or epidermal growth  
factor in cervical squamous cell and breast carcinoma cell lines.  
Repression was dependent on the adjacent AP-1 site, without discernible  
alteration in the binding affinity or **composition** of AP-1. We  
investigated the following two possible mechanisms for E-box-mediated  
repression: 1) CpG methylation of the core of the E-box element, and 2)  
binding of a distinct protein complex to this site. Point mutation of the  
CpG methylation site in the E-box showed loss of repressor activity.  
Conversely, in vitro methylation of this site significantly reduced TPA  
**induction**. In vitro gel shift analysis revealed distinct and  
TPA-dependent binding of USF1 and USF2 to the repressor element that  
required nucleotides within the E-box. Furthermore, chromatin  
immunoprecipitation assay showed that USF, c-Myc, and Max proteins were  
associated with the FGF-BP promoter in vivo. Overall, these findings  
suggested that the balance between trans-activation by AP-1 and  
repression

through the E-box is an important control mechanism for fine-tuning the  
angiogenic response to growth factor-activated pathways.

ACCESSION NUMBER: 2000496098 MEDLINE  
DOCUMENT NUMBER: 20435808

TITLE: Mitogen-induced expression of the fibroblast growth factor-binding protein is transcriptionally repressed through a non-canonical E-box element.

AUTHOR: Harris V K; Coticchia C M; List H J; Wellstein A; Riegel A T

CORPORATE SOURCE: Department of Oncology, Vincent T. Lombardi Cancer Center, Georgetown University, Washington, D. C. 20007, USA.

CONTRACT NUMBER: CA71508 (NCI)

SOURCE: JOURNAL OF BIOLOGICAL CHEMISTRY, (2000 Sep 15) 275 (37) 28539-48.  
Journal code: HIV. ISSN: 0021-9258.

PUB. COUNTRY: United States  
Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals; Cancer Journals

ENTRY MONTH: 200012

ENTRY WEEK: 20001204

L3 ANSWER 2 OF 2 MEDLINE

TI Cellular and molecular mechanisms of tumor invasion.

AB This review summarizes data on cellular and molecular mechanisms underlying phenotypical characteristics of tumor cells that determine their ability for invasion. These mechanisms include dysregulation of adhesive interactions of tumor cells with each other and with extracellular matrix, protease production, locomotion reactions of tumor cells, and induction of angiogenesis in tumor. Data on structure and functions of transmembrane adhesion molecules and their ligands, molecular composition of adhesion structures (intercellular and focal contacts), and role of adhesion molecules as transducers of intracellular signals are considered. Alterations of expression of adhesion molecules and cytoplasmic proteins in adhesion structures and hyperphosphorylation of these molecules by oncogene products are described as a precondition of invasion activity of tumor cells. The contact interaction between circulating tumor cells and vascular endothelium is considered as the important stage of the metastatic process. Secretion of proteases by tumor cells and regulation of their activity by specific stromal inhibitors are described. Function of motogens in the acquisition by a tumor cell of locomotor phenotype facilitating invasion and impairments of topographic reactions of cells playing an important role in the invasion are considered. Attention is given to mechanisms of neoangiogenesis in the tumor providing additional ways for dissemination of tumor cells.

ACCESSION NUMBER: 1999014055 MEDLINE

DOCUMENT NUMBER: 99014055

TITLE: Cellular and molecular mechanisms of tumor invasion.

AUTHOR: Rovensky Y A

CORPORATE SOURCE: Blokhin Cancer Research Center, Russian Academy of Medical Sciences, Moscow, 115478, Russia.. jury@vasiliev.msk.su

SOURCE: BIOCHEMISTRY, (1998 Sep) 63 (9) 1029-43. Ref: 169  
Journal code: CSQ. ISSN: 0006-2979.

PUB. COUNTRY: RUSSIA: Russian Federation  
Journal; Article; (JOURNAL ARTICLE)  
General Review; (REVIEW)  
(REVIEW, ACADEMIC)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199903

=> file biosis, frosti, biotechds, biotechabs, uspat, hcaplus, wpids, japio, fsta, cen, dgene, embase, scisearch

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

FILE 'BIOSIS' ENTERED AT 16:39:36 ON 30 NOV 2000  
COPYRIGHT (C) 2000 BIOSIS(R)

FILE 'FROSTI' ENTERED AT 16:39:36 ON 30 NOV 2000  
COPYRIGHT (C) 2000 Leatherhead Food Research Association

FILE 'BIOTECHDS' ENTERED AT 16:39:36 ON 30 NOV 2000  
COPYRIGHT (C) 2000 DERWENT INFORMATION LTD

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'USPATFULL' ENTERED AT 16:39:36 ON 30 NOV 2000  
CA INDEXING COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'HCAPLUS' ENTERED AT 16:39:36 ON 30 NOV 2000  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 16:39:36 ON 30 NOV 2000  
COPYRIGHT (C) 2000 DERWENT INFORMATION LTD

FILE 'JAPIO' ENTERED AT 16:39:36 ON 30 NOV 2000  
COPYRIGHT (C) 2000 Japanese Patent Office (JPO)

FILE 'FSTA' ENTERED AT 16:39:36 ON 30 NOV 2000  
COPYRIGHT (C) 2000 International Food Information Service

FILE 'CEN' ENTERED AT 16:39:36 ON 30 NOV 2000  
COPYRIGHT (C) 2000 American Chemical Society (ACS)

FILE 'DGENE' ENTERED AT 16:39:36 ON 30 NOV 2000  
COPYRIGHT (C) 2000 DERWENT INFORMATION LTD

FILE 'EMBASE' ENTERED AT 16:39:36 ON 30 NOV 2000  
COPYRIGHT (C) 2000 Elsevier Science B.V. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 16:39:36 ON 30 NOV 2000  
COPYRIGHT (C) 2000 Institute for Scientific Information (ISI) (R)

=> s 11

L4 4787 L1

=> s 12

L5 2 L2

=> s 14 and 15

L6 0 L4 AND L5

=> d 15 ti abs ibib tot

L5 ANSWER 1 OF 2 USPATFULL

TI Procaryotic xylose isomerase muteins

AB Xylose isomerase (XI) muteins useful in the conversion of glucose to  
fructose or xylose to xylulose are obtained in usable amounts by  
protein

structural and recombinant DNA methods, including x-ray crystallography, cloning, computer graphic modeling and site-directed mutagenesis and expression of the bacterial DNA sequences encoding native procaryotic xylose isomerase. These native sequences are altered to encode the xylose isomerase muteins having improved catalytic function and/or thermostability.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 91:66732 USPATFULL  
TITLE: Procaryotic xylose isomerase muteins  
INVENTOR(S): Drummond, Robert J., Richmond, CA, United States  
Bloch, Will, El Cerrito, CA, United States  
Matthews, Brian W., Eugene, OR, United States  
Toy, Pamela L., Oakland, CA, United States  
PATENT ASSIGNEE(S): Cetus Corporation, Emeryville, CA, United States (U.S. corporation)  
Univerity of Oregon, Eugene, OR, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5041378	19910820
APPLICATION INFO.:	US 1987-84479	19870811 (7)
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Teskin, Robin L.	
ASSISTANT EXAMINER:	Peet, Richard C.	
LEGAL REPRESENTATIVE:	Mendel, SaraLynn	
NUMBER OF CLAIMS:	1	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 7 Drawing Page(s)	
LINE COUNT:	2240	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 2 OF 2 USPATFULL

TI Enzymatically inactive, immunologically-active .beta.-galactosidase  
muetin, process for making and uses thereof

AB The present invention provides an enzymatically-inactive, immunologically-active .beta.-galactosidase mutein, wherein, in the region between the amino acids 430 and 550, at least one amino acid of the natural sequence is changed to another amino acid and the enzymatic activity does not amount to more than 1%, referred to the native enzyme.

The present invention also provides a process for the production of this

mutein. Furthermore, the present invention is concerned with the use of this mutein in the immunological determination of serum proteins by the enzyme immunoassay principle.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 90:79799 USPATFULL  
TITLE: Enzymatically inactive, immunologically-active .beta.-galactosidase muetin, process for making and uses thereof  
INVENTOR(S): Mattes, Ralf, Stuttgart, Germany, Federal Republic of  
Lenz, Helmut, Tutzing, Germany, Federal Republic of  
Stock, Werner, Grafelfing, Germany, Federal Republic  
of  
PATENT ASSIGNEE(S): Boehringer Mannheim GmbH, Mannheim, Germany, Federal Republic of (non-U.S. corporation)

NUMBER	DATE
-----	-----

PATENT INFORMATION: US 4963469 19901016  
APPLICATION INFO.: US 1988-218816 19880712 (7)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1987-3724625	19870724
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Weimer, Elizabeth C.	
ASSISTANT EXAMINER:	Spiegel, Carol A.	
LEGAL REPRESENTATIVE:	Felfe and Lynch	
NUMBER OF CLAIMS:	22	
EXEMPLARY CLAIM:	10	
NUMBER OF DRAWINGS:	7 Drawing Figure(s); 6 Drawing Page(s)	
LINE COUNT:	802	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 16:37:43 ON 30 NOV 2000)

FILE 'MEDLINE' ENTERED AT 16:37:58 ON 30 NOV 2000

L1 669 S ANGIOGENESIS AND (INDUCTION)  
L2 0 S MUETIN  
L3 2 S L1 AND COMPOSITION

FILE 'BIOSIS, FROSTI, BIOTECHDS, USPATFULL, HCAPLUS, WPIDS, JAPIO, FSTA, CEN, DGENE, EMBASE, SCISEARCH' ENTERED AT 16:39:36 ON 30 NOV 2000

L4 4787 S L1  
L5 2 S L2  
L6 0 S L4 AND L5

=> s l4 and composition

L7 752 L4 AND COMPOSITION

=> s l7 and unit dose

L8 53 L7 AND UNIT DOSE

=> s l8 and (myocardial infarction)

L9 6 L8 AND (MYOCARDIAL INFARCTION)

=> d l9 ti abs ibib tot

L9 ANSWER 1 OF 6 USPATFULL

TI Compositions and methods for regulation of active TNF-.alpha.

AB Substances comprising disaccharides and substances comprising carboxylated and/or sulfated oligosaccharides in substantially purified form, and methods of using same, are disclosed for the regulation of cytokine activity in a host. For instance, the secretion of active

Tumor

Necrosis Factor Alpha (TNF-.alpha.) can be either inhibited or augmented selectively by administration to the host of an effective amount of a substance of the invention. Thus, the present invention also relates to pharmaceutical compositions and their use for the prevention and/or treatment of pathological processes involving the induction of active cytokine secretion, such as TNF-.alpha.. The invention also relates to the initiation of a desirable immune system-related response

by the host to the presence of activators, including pathogens. The substances and pharmaceutical compositions of the present invention may be administered daily, at very low effective doses, typically below 0.1 mg/kg human, or at intervals of up to about 5-8 days, preferably once a week.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2000:12786 USPATFULL  
TITLE: Compositions and methods for regulation of active TNF-.alpha.  
INVENTOR(S): Cohen, Irun R., Rehovot, Israel  
Lider, Ofer, Rehovot, Israel  
Cahalon, Liora, Givataim, Israel  
Shoseyov, Oded, Shimshon, Israel  
Margalit, Raanan, Rehovot, Israel  
PATENT ASSIGNEE(S): Yeda Research and Development Co. Ltd., Rehovot, Israel  
(non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 6020323	20000201
APPLICATION INFO.:	US 1995-486127	19950607 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-436330, filed on 10 May 1995 which is a continuation-in-part of Ser. No. US 1993-96739, filed on 23 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-974750, filed on 10 Nov 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-878188, filed on 1 May 1992, now abandoned	
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Achutamurthy, Ponnathapura	
ASSISTANT EXAMINER:	Ponnaluri, P.	
LEGAL REPRESENTATIVE:	Pennie & Edmonds LLP	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	65 Drawing Figure(s); 54 Drawing Page(s)	
LINE COUNT:	3440	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 2 OF 6 USPATFULL

TI Methods of using low molecular weight heparins for prevention or treatment of pathological processes

AB The present invention relates to pharmaceutical compositions for the prevention and/or treatment of pathological processes involving the induction of TNF-.alpha. secretion comprising a pharmaceutically acceptable carrier and a low molecular weight heparin (LMWH). In the pharmaceutical compositions of the present invention, the LMWH is present in a low effective dose and is administered at intervals of about 5-8 days. Furthermore, the LMWH is capable of inhibiting in vitro TNF-.alpha. secretion by resting T cells and/or macrophages in response to T cell-specific antigens, mitogens, macrophage activators, disrupted extracellular matrix (dECM), laminin, fibronectin, and the like.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1999:63310 USPATFULL  
TITLE: Methods of using low molecular weight heparins for prevention or treatment of pathological processes  
INVENTOR(S): Cohen, Irun R., Rehovot, Israel  
Lider, Ofer, Rehovot, Israel  
Hershkoviz, Rami, Herzliya, Israel  
PATENT ASSIGNEE(S): Yeda Research and Development Co. Ltd., Rehovot, Israel

(non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5908837	19990601
APPLICATION INFO.:	US 1997-966315	19971107 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-457655, filed on 1 Jun 1995, now patented, Pat. No. US 5686431 which is a continuation of Ser. No. US 1995-384203, filed on 3 Feb 1995, now patented, Pat. No. US 5474987 which is a continuation of Ser. No. US 1992-878188, filed on 1 May 1992, now abandoned	

	NUMBER	DATE
PRIORITY INFORMATION:	IL 1991-98028	19910502
	IL 1991-98298	19910528
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Fonda, Kathleen K.	
LEGAL REPRESENTATIVE:	Pennie & Edmonds LLP	
NUMBER OF CLAIMS:	12	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Figure(s); 8 Drawing Page(s)	
LINE COUNT:	919	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L9 ANSWER 3 OF 6 USPATFULL

TI Methods for regulation of active TNF-.alpha.

AB Substances comprising disaccharides and substances comprising carboxylated and/or sulfated oligosaccharides in substantially purified form, and methods of using same, are disclosed for the regulation of cytokine activity in a host. For instance, the secretion of active

Tumor

augmented Necrosis Factor Alpha (TNF-.alpha.) can be either inhibited or

selectively by administration to the host of an effective amount of a substance of the invention. Thus, the present invention also relates to pharmaceutical compositions and their use for the prevention and/or treatment of pathological processes involving the induction of active cytokine secretion, such as TNF-.alpha.. The invention also relates to the initiation of a desirable immune system-related response by the host to the presence of activators, including pathogens. The substances and pharmaceutical compositions of the present invention may be administered daily, at very low effective doses, typically below 0.1 mg/kg human, or at intervals of tip to about 5-8 days, preferably once

a

week.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1999:7369 USPATFULL

TITLE: Methods for regulation of active TNF-.alpha.

INVENTOR(S): Cohen, Irun R., Rehovot, Israel

Lider, Ofer, Rehovot, Israel

Cahalon, Liora, Givataim, Israel

Shoseyov, Oded, Shimshon, Israel

Margalit, Raanan, Rehovot, Israel

PATENT ASSIGNEE(S): Yeda Research and Development Co. Ltd., Israel  
(non-U.S. corporation)

NUMBER	DATE
--------	------



PATENT INFORMATION: US 5861382 19990119  
 WO 9411006 19940526  
 APPLICATION INFO.: US 1995-436330 19950629 (8)  
 WO 1993-US10868 19931109  
 19950629 PCT 371 date  
 19950629 PCT 102(e) date  
 RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1993-96739, filed  
 on 23 Jul 1993, now abandoned And a  
 continuation-in-part of Ser. No. US 1992-974750, filed  
 on 10 Nov 1992, now abandoned which is a  
 continuation-in-part of Ser. No. US 1992-878188, filed  
 on 1 May 1992, now abandoned And a continuation of  
 Ser. No. US 1995-384203, filed on 3 Feb 1995, now  
 patented, Pat. No. US 5474987  
 DOCUMENT TYPE: Utility  
 PRIMARY EXAMINER: Achutamurthy, Ponnathapura  
 ASSISTANT EXAMINER: Ponnaluri, Padmashri  
 LEGAL REPRESENTATIVE: Pennie & Edmonds LLP  
 NUMBER OF CLAIMS: 5  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 65 Drawing Figure(s); 54 Drawing Page(s)  
 LINE COUNT: 3391  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 4 OF 6 USPATFULL  
 TI Integrin receptor antagonists  
 AB This invention relates to novel heterocycle compounds including but not  
 limited to 3-[3-[3-(imidazolin-2-yl amino)propyloxy]isoxazol-5-  
 ylcarbonylamino]-2-(benzyloxycarbonylamino)-propionic acid, which are  
 useful as antagonists of the .alpha..sub.v .beta..sub.3 and related  
 integrin receptors, to pharmaceutical compositions containing such  
 compounds, processes for preparing such compounds, and to methods of  
 using these compounds, alone or in combination with other therapeutic  
 agents, for the inhibition of cell adhesion and the treatment of  
 angiogenic disorders, inflammation, bone degradation, tumors,  
 metastases, thrombosis, and other cell aggregation-related conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1998:7077 USPATFULL  
 TITLE: Integrin receptor antagonists  
 INVENTOR(S): Voss, Matthew Ernst, Lincoln University, PA, United  
 States  
 Jadhav, Prabhakar Kondaji, Wilmington, DE, United  
 States  
 Smallheer, Joanne Marie, Landenberg, PA, United States  
 Batt, Douglas Guy, Wilmington, DE, United States  
 Pitts, William John, Conshohocken, PA, United States  
 Wityak, John, West Grove, PA, United States  
 PATENT ASSIGNEE(S): The DuPont Merck Pharmaceutical Company, Wilmington,  
 DE, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5710159	19980120
APPLICATION INFO.:	US 1996-647132	19960509 (8)
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	McKane, Joseph	
LEGAL REPRESENTATIVE:	Ferguson, Blair Q.	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1	
LINE COUNT:	6665	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 5 OF 6 PATFULL

TI Methods of using low molecular weight heparins for treatment of pathological processes

AB The present invention relates to methods for the prevention and/or treatment of pathological processes involving the **induction** of TNF-.alpha. secretion comprising a pharmaceutically acceptable carrier and a low molecular weight heparin (LMWH). In the pharmaceutical compositions of the present invention, the LMWH present in a low effective dose and is administered at intervals of about 5-8 days. Furthermore, the LMWH is capable of inhibiting in vitro TNF-.alpha. secretion by resting T cells and/or macrophages in response to T cell-specific antigens, mitogens, macrophage activators, disrupted extracellular matrix (dECM), laminin, fibronectin, and the like.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 97:104459 USPATFULL

TITLE: Methods of using low molecular weight heparins for treatment of pathological processes

INVENTOR(S): Cohen, Irun R., Rehovot, Israel  
Lider, Ofer, Rehovot, Israel

PATENT ASSIGNEE(S): Hershkoviz, Rami, Herzliya, Israel  
Yeda Research and Development Co., Ltd., Israel  
(non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5686431	19971111
APPLICATION INFO.:	US 1995-457655	19950601 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-384203, filed on 3 Feb	
	1995, now patented, Pat. No. US 5474987 which is a continuation of Ser. No. US 1992-878188, filed on 1 May	
	1992, now abandoned	

	NUMBER	DATE
PRIORITY INFORMATION:	IL 1991-98028	19910502
	IL 1991-98298	19910528
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Fonda, Kathleen K.	
LEGAL REPRESENTATIVE:	Pennie & Edmonds	
NUMBER OF CLAIMS:	4	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Figure(s); 8 Drawing Page(s)	
LINE COUNT:	907	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 6 OF 6 USPATFULL

TI Methods of using low molecular weight heparins treatment of pathological processes

AB The present invention relates to methods for the prevention and/or treatment of pathological processes involving the **induction** of TNF-.alpha. secretion comprising a pharmaceutically acceptable carrier and a low molecular weight heparin (LMWH). In the pharmaceutical compositions of the present invention, the LMWH is present in a low effective dose and is administered at intervals of about 5-8 days. Furthermore, the LMWH is capable of inhibiting in vitro TNF-.alpha. secretion by resting T cells and/or macrophages in response to T cell-specific antigens, mitogens, macrophage activators, disrupted extracellular matrix (dECM), laminin, fibronectin, and the like.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
ACCESSION NUMBER: 95:110435 USPATFULL  
TITLE: Methods of using low molecular weight heparins  
treatment of pathological processes  
INVENTOR(S): Cohen, Irun R., Herzliya, Israel  
Lider, Ofer, Herzliya, Israel  
Hershkoviz, Rami, Herzliya, Israel  
PATENT ASSIGNEE(S): Yeda Research and Development Co. Ltd., Israel  
(non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5474987	19951212
APPLICATION INFO.:	US 1995-384203	19950203 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1992-878188, filed on 1 May 1992, now abandoned	

	NUMBER	DATE
PRIORITY INFORMATION:	IL 1991-98028	19910502
	IL 1991-98298	19910528
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Robinson, Douglas W.	
ASSISTANT EXAMINER:	Fonda, Kathleen Kahler	
LEGAL REPRESENTATIVE:	Pennie & Edmonds	
NUMBER OF CLAIMS:	6	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Figure(s); 8 Drawing Page(s)	
LINE COUNT:	860	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.